The global thalassemia market is anticipated to grow at a CAGR of 11.2% during the forecast period. Thalassemia is a genetic blood disorder in which hemoglobin is produced in an abnormal form. This leads to the destruction of a large number of blood cells, resulting in anemia. The disorder is caused by genetic mutation or due to the deletion of a specific gene fragment. There are three types of thalassemia viz. alpha thalassemia, beta-thalassemia, and thalassemia minor. The treatment of the disease depends on its severity and type. The patients suffering from beta and those with alpha thalassemia manifest more severe symptoms than thalassemia minor. Common symptoms are bone deformities, dark urine, excessive fatigue, and pale skin.
Top Driver: Growing Incidence of Thalassemia and Demand for Curative Gene Therapy
The growing incidence of thalassemia is a major factor anticipated to drive the growth of the market. It is estimated that thalassemia affects approximately 4.4 of every 10,000 live births across the world. Moreover, increase penetration of drugs in thalassemia is another major factor fueling the growth of the market. There are around 15 pipeline products under clinical trials for thalassemia therapy. Besides, the rise in awareness concerning the availability of treatment options and the rise in demand for improved curative gene therapy is anticipated to propel the global thalassemia market.
Gene Therapy to Make Crucial Contribution to Growth of Global Cognitive Computing Market
On the basis of treatment type the market is segmented into Blood Transfusions, Iron Chelation Therapy, Gene Therapy, Others. The gene therapy market is expected to be the largest and fastest growing segment since gene therapy has showed some promising results in the treatment of thalassemia and is been widely adopted for treatment. On the basis of dieses type the market is segmented as Alpha Thalassemia, Beta Thalassemia. On the basis of end use the market is segmented into Hospitals, Research Institutes, Others.

Rising Investments in Gene Therapy to Benefit North America Market
The European countries are anticipated gain the largest share among the seven major markets followed by U.S. and Japan. Furthermore, introduction of gene therapy for the treatment of thalassemia is anticipated to propel the market share of the U.S. and EU. The higher adoption of gene therapy for thalassemia treatment will be comparatively slower and however, significant growth is expected in the coming years. The growth in the research and development is expected to help the industry in the coming years.

Players to Focus on Thalassemia Market
The global market is expected to stay fragmented with the increase in the number of new entrants in the coming years. Bluebird bio, Inc., Acceleron Pharma, Inc., Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, Gamida Cell, Kiadis Pharma, La Jolla Pharmaceutical Company, and IONIS Pharmaceuticals among others could be at the forefront of the competition in the global market.
Celgene Corporation: In November 2019, Bristol-Myers Squibb Company announced that it had completed its acquisition of Celgene Corporation following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
bluebird bio, Inc.: In January 2020, bluebird bio, Inc. announced the launch in Germany of ZYNTEGLO, a one-time gene therapy for patients 12 years and older with transfusion-dependent ?-thalassemia (TDT) who do not have a ?0/?0 genotype, for whom hematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)-matched related HSC donor is not available. This is the first time ZYNTEGLO is commercially available.
Scope of the Report
By Treatment Type
” Blood Transfusions
” Iron Chelation Therapy
” Gene Therapy
” Others

By Disease Type
” Alpha Thalassemia
” Beta Thalassemia
By End-User
” Hospitals
” Research Institutes
” Others
By Region
” North America
” Europe
” Asia Pacific
” SAMEA

Key Reasons to Purchase this Report
1. It provides a technological development map over time to understand the growth rate of the industry.
2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.
3. It renders definite analysis for changing competitive dynamics.
4. It builds a seven-year estimate based on how the market is predicted to grow.